Neurofibromatosis Type 1
A genetic condition causing tumors to grow on nerves throughout the body, along with characteristic skin spots and bone abnormalities.
Emergency Management: Spinal cord compression from a paraspinal neurofibroma causing acute paraparesis or bowel/bladder dysfunction requires emergent neurosurgical decompression.
Neurofibromatosis Type 1 (NF1) is an autosomal dominant multisystem genetic disorder caused by mutations in the NF1 gene. It is characterized by the development of multiple benign tumors of nerves and skin (neurofibromas), areas of abnormal skin pigmentation, and various skeletal, neurological, and oncological manifestations.
Detailed Overview
NF1 is one of the most common neurogenetic disorders. The NF1 gene encodes neurofibromin, a tumor suppressor protein that negatively regulates the RAS signaling pathway. Loss of neurofibromin leads to uncontrolled cell proliferation. Clinical features typically appear in early childhood, starting with café-au-lait macules and axillary freckling, followed by Lisch nodules in the eyes and neurofibromas. While most tumors are benign, patients have a high risk of developing malignant peripheral nerve sheath tumors (MPNST), optic pathway gliomas, and other cancers. Management requires multidisciplinary lifelong surveillance.
Epidemiology & Demographics
Incidence is roughly 1 in 3,000 live births worldwide. It affects all ethnicities and both sexes equally. About 50% of cases are familial, and 50% represent de novo mutations.
Etiological Mechanism
Caused by heterozygous loss-of-function mutations in the NF1 gene located on chromosome 17q11.2.
Primary Causes
Inherited mutation of the NF1 gene (autosomal dominant)
Spontaneous de novo mutation of the NF1 gene
The NF1 gene encodes neurofibromin, a GTPase-activating protein (GAP) that normally inactivates RAS by converting active RAS-GTP to inactive RAS-GDP. Mutation results in non-functional neurofibromin, leading to constitutively active RAS signaling. This drives the MAPK and PI3K/mTOR pathways, promoting rampant cellular proliferation and tumorigenesis, particularly in Schwann cells, melanocytes, and bone cells. A 'second hit' (somatic mutation of the remaining normal allele) in Schwann cells is required for the formation of neurofibromas.
Diagnostic Criteria & Guidelines
Diagnosis is clinical, requiring ≥ 2 of the following: 1) ≥6 café-au-lait macules, 2) ≥2 neurofibromas or 1 plexiform neurofibroma, 3) Axillary/inguinal freckling, 4) Optic glioma, 5) ≥2 Lisch nodules, 6) Distinctive osseous lesion, 7) First-degree relative with NF1. Recent updates allow genetic testing (pathogenic NF1 variant) to serve as a criterion.
No cure exists. Management is symptomatic and surveillance-based. Cutaneous neurofibromas causing pain or severe cosmetic distress can be surgically excised or treated with CO2 laser. For symptomatic, inoperable plexiform neurofibromas in children >2 years, Selumetinib (a MEK inhibitor) is FDA-approved, dosed 25 mg/m² PO BID, reducing tumor volume.
Second-Line & Adjunctive Therapy
For Optic Pathway Gliomas causing visual decline, Carboplatin/Vincristine chemotherapy is the standard; radiation is avoided to prevent secondary malignancies. MPNST requires aggressive surgical resection with wide margins, often combined with adjuvant radiation and chemotherapy (Doxorubicin/Ifosfamide).
Surgical & Procedural Management
Surgical excision of symptomatic neurofibromas. Orthopedic surgery for severe scoliosis or tibial pseudarthrosis.
Patient Counseling & Advice
Counsel that disease severity is highly variable, even within families. Instruct patients to report rapid growth, new persistent pain, or hardening of any existing neurofibroma immediately, as these are signs of malignant transformation (MPNST). Offer genetic counseling for family planning.
Follow-Up & Monitoring Schedule
Multidisciplinary NF clinic annually: full skin check, neurological exam, BP check, and ophthalmologic evaluation.
Preventive Strategies
Cannot be prevented except through preimplantation genetic diagnosis (PGD) in known carrier parents.
Life expectancy is reduced by 10-15 years compared to the general population, primarily due to malignancies (MPNST) and cardiovascular complications.